UK markets closed
NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.31 -0.05 (-0.06%) GOLD FUTURES
2,399.50 +16.50 (+0.69%) DOW
37,798.97 +63.86 (+0.17%) Bitcoin GBP
51,733.55 +964.27 (+1.90%)
Lonza Group Ltd (LZAGF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 11:16AM EDT
| Previous close | 577.68 |
| Open | 581.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 572.53 - 581.10 |
| 52-week range | 336.03 - 661.60 |
| Volume | |
| Avg. volume | 1,237 |
| Market cap | 41.762B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | 59.02 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.57 (0.79%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- Business Wire
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
© 2024 Yahoo. All rights reserved.